153 related articles for article (PubMed ID: 22994941)
1. Phase I study of miriplatin combined with transarterial chemotherapy using CDDP powder in patients with hepatocellular carcinoma.
Kamimura K; Suda T; Tamura Y; Takamura M; Yokoo T; Igarashi M; Kawai H; Yamagiwa S; Nomoto M; Aoyagi Y
BMC Gastroenterol; 2012 Sep; 12():127. PubMed ID: 22994941
[TBL] [Abstract][Full Text] [Related]
2. Transhepatic arterial infusion chemotherapy using a combination of miriplatin and CDDP powder versus miriplatin alone in the treatment of hepatocellular carcinoma: a randomized controlled trial.
Kamimura K; Suda T; Yokoo T; Kamimura H; Kanefuji T; Tsuchiya A; Takamura M; Kawai H; Waguri N; Yamagiwa S; Terai S
BMC Cancer; 2017 May; 17(1):322. PubMed ID: 28490356
[TBL] [Abstract][Full Text] [Related]
3. Phase I/II study of the lipiodolization using DDP-H (CDDP powder; IA-call(®)) in patients with unresectable hepatocellular carcinoma.
Yamashita Y; Taketomi A; Itoh S; Harimoto N; Morita K; Fukuhara T; Ueda S; Sanefuji K; Sugimachi K; Tajima T; Maehara Y
Cancer Chemother Pharmacol; 2010 Jan; 65(2):301-7. PubMed ID: 19495755
[TBL] [Abstract][Full Text] [Related]
4. Switch to miriplatin for multinodular hepatocellular carcinoma unresponsive to transarterial chemoembolization with epirubicin: a prospective study.
Goda Y; Morimoto M; Irie K; Kobayashi S; Ueno M; Moriya S; Tezuka S; Ohkawa S; Morinaga S; Numata K; Tanaka K; Maeda S
Jpn J Clin Oncol; 2017 Dec; 47(12):1151-1156. PubMed ID: 28977459
[TBL] [Abstract][Full Text] [Related]
5. A transcatheter arterial chemotherapy using a novel lipophilic platinum derivative (miriplatin) for patients with small and multiple hepatocellular carcinomas.
Yukisawa S; Ishii H; Kasuga A; Matsuyama M; Kuraoka K; Takano K; Ozaka M
Eur J Gastroenterol Hepatol; 2012 May; 24(5):583-8. PubMed ID: 22330234
[TBL] [Abstract][Full Text] [Related]
6. Usefulness of miriplatin as an anticancer agent for transcatheter arterial chemoembolization in patients with unresectable hepatocellular carcinoma.
Imai Y; Chikayama T; Nakazawa M; Watanabe K; Ando S; Mizuno Y; Yoshino K; Sugawara K; Hamaoka K; Fujimori K; Inao M; Nakayama N; Oka M; Nagoshi S; Mochida S
J Gastroenterol; 2012 Feb; 47(2):179-86. PubMed ID: 21976133
[TBL] [Abstract][Full Text] [Related]
7. Effect of double platinum agents, combination of miriplatin-transarterial oily chemoembolization and cisplatin-hepatic arterial infusion chemotherapy, in patients with hepatocellular carcinoma: Report of two cases.
Ogawa K; Kamimura K; Watanabe Y; Motai Y; Kumaki D; Seki R; Sakamaki A; Abe S; Kawai H; Suda T; Yamagiwa S; Terai S
World J Clin Cases; 2017 Jun; 5(6):238-246. PubMed ID: 28685137
[TBL] [Abstract][Full Text] [Related]
8. Safety and short-term therapeutic effects of miriplatin-lipiodol suspension in transarterial chemoembolization (TACE) for hepatocellular carcinoma.
Okabe K; Beppu T; Haraoka K; Oh-Uchida Y; Yamamura S; Tomiyasu S; Yamanaka T; Sano O; Masuda T; Chikamoto A; Fujiyama S; Baba H
Anticancer Res; 2011 Sep; 31(9):2983-8. PubMed ID: 21868548
[TBL] [Abstract][Full Text] [Related]
9. Intra-hepatic arterial administration with miriplatin suspended in an oily lymphographic agent inhibits the growth of tumors implanted in rat livers by inducing platinum-DNA adducts to form and massive apoptosis.
Hanada M; Baba A; Tsutsumishita Y; Noguchi T; Yamaoka T; Chiba N; Nishikaku F
Cancer Chemother Pharmacol; 2009 Aug; 64(3):473-83. PubMed ID: 19104812
[TBL] [Abstract][Full Text] [Related]
10. Hepatic artery infusion chemotherapy using mFOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma: a prospective non-randomized study.
He MK; Le Y; Li QJ; Yu ZS; Li SH; Wei W; Guo RP; Shi M
Chin J Cancer; 2017 Oct; 36(1):83. PubMed ID: 29061175
[TBL] [Abstract][Full Text] [Related]
11. Initial safety and outcomes of miriplatin plus low-dose epirubicin for transarterial chemoembolisation of hepatocellular carcinoma.
Iwazawa J; Hashimoto N; Ohue S; Mitani T
Anticancer Res; 2012 Nov; 32(11):5039-44. PubMed ID: 23155276
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the anti-tumor effects of two platinum agents (miriplatin and fine-powder cisplatin).
Watanabe S; Nitta N; Ohta S; Sonoda A; Otani H; Tomozawa Y; Nitta-Seko A; Tsuchiya K; Tanka T; Takahashi M; Murata K
Cardiovasc Intervent Radiol; 2012 Apr; 35(2):399-405. PubMed ID: 21584842
[TBL] [Abstract][Full Text] [Related]
13. Synergistic anti-tumor activity of miriplatin and radiation through PUMA-mediated apoptosis in hepatocellular carcinoma.
Tanaka H; Okamoto K; Sato Y; Tanaka T; Tomonari T; Nakamura F; Fujino Y; Mitsui Y; Miyamoto H; Muguruma N; Morita A; Ikushima H; Takayama T
J Gastroenterol; 2020 Nov; 55(11):1072-1086. PubMed ID: 32666201
[TBL] [Abstract][Full Text] [Related]
14. Previous chemoembolization response after transcatheter arterial chemoembolization (TACE) can predict the anti-tumor effect of subsequent TACE with miriplatin in patients with recurrent hepatocellular carcinoma.
Imai N; Ikeda K; Seko Y; Kawamura Y; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Saitoh S; Suzuki F; Suzuki Y; Arase Y; Kumada H
Oncology; 2011; 80(3-4):188-94. PubMed ID: 21709428
[TBL] [Abstract][Full Text] [Related]
15. [Transcatheter arterial chemotherapy with miriplatin for patients with hepatocellular carcinoma and chronic renal failure].
Imai N; Ikeda K; Seko Y; Matsumoto N; Kawamura Y; Hosaka T; Kobayashi M; Saitoh S; Sezaki H; Akuta N; Suzuki F; Suzuki Y; Arase Y; Kumada H
Nihon Shokakibyo Gakkai Zasshi; 2011 Nov; 108(11):1872-8. PubMed ID: 22056708
[TBL] [Abstract][Full Text] [Related]
16. Intra-arterial idarubicin_lipiodol without embolisation in hepatocellular carcinoma: The LIDA-B phase I trial.
Guiu B; Jouve JL; Schmitt A; Minello A; Bonnetain F; Cassinotto C; Piron L; Cercueil JP; Loffroy R; Latournerie M; Wendremaire M; Lepage C; Boulin M
J Hepatol; 2018 Jun; 68(6):1163-1171. PubMed ID: 29427728
[TBL] [Abstract][Full Text] [Related]
17. Intra-hepatic arterial administration with miriplatin suspended in an oily lymphographic agent inhibits the growth of human hepatoma cells orthotopically implanted in nude rats.
Hanada M; Baba A; Tsutsumishita Y; Noguchi T; Yamaoka T
Cancer Sci; 2009 Jan; 100(1):189-94. PubMed ID: 19037997
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of transcatheter arterial chemoembolization with miriplatin-lipiodol water-soluble contrast agent emulsion in patients with hepatocellular carcinoma.
Okimoto K; Ogasawara S; Chiba T; Ooka Y; Oobu M; Azemoto R; Kanogawa N; Motoyama T; Suzuki E; Tawada A; Yoshikawa M; Yokosuka O
Anticancer Res; 2013 Dec; 33(12):5603-9. PubMed ID: 24324105
[TBL] [Abstract][Full Text] [Related]
19. Transarterial infusion chemotherapy using cisplatin-lipiodol suspension with or without embolization for unresectable hepatocellular carcinoma.
Kawaoka T; Aikata H; Takaki S; Katamura Y; Hiramatsu A; Waki K; Takahashi S; Hieda M; Toyota N; Ito K; Chayama K
Cardiovasc Intervent Radiol; 2009 Jul; 32(4):687-94. PubMed ID: 19444503
[TBL] [Abstract][Full Text] [Related]
20. Transarterial chemoembolization with miriplatin plus epirubicin in patients with hepatocellular carcinoma.
Tawada A; Chiba T; Ooka Y; Kanogawa N; Saito T; Motoyama T; Ogasawara S; Suzuki E; Kanai F; Yoshikawa M; Yokosuka O
Anticancer Res; 2015 Jan; 35(1):549-54. PubMed ID: 25550601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
